Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right…